• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by GeneDx Holdings Corp.

    9/30/25 8:04:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $WGS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001689575
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    GeneDx Holdings Corp.
    SEC File Number
    001-39482
    Address of Issuer
    333 Ludlow St, North Tower
    6th Floor
    Stamford
    CONNECTICUT
    06902
    Phone
    888-729-1206
    Name of Person for Whose Account the Securities are To Be Sold
    Katherine Stueland
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A Common Stock
    Morgan Stanley Smith Barney
    2000 Westchester Avenue
    Purchase � NY � 10577
    1642517696002872624809/30/2025
    NASDAQ
    Class A Common Stock
    Merrill Lynch
    2049 Century Park E
    Ste 1200
    Los Angeles � CA � 90067
    1285813909122872624809/30/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A Common Stock05/02/2022Acquired as compensation - Restricted Stock UnitsIssuerCheckbox not checked390205/02/2022Compensation
    Class A Common Stock12/09/2022Acquired as compensation - Restricted Stock UnitsIssuerCheckbox not checked657512/09/2022Compensation
    Class A Common Stock04/26/2023Acquired as compensation - Restricted Stock UnitsIssuerCheckbox not checked1880604/26/2023Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Katherine Stueland
    333 Ludlow St, North Tower
    6th Floor
    Stamford � CT � 06902
    Class A Common Stock07/01/20259657878181
    Katherine Stueland
    333 Ludlow St, North Tower
    6th Floor
    Stamford � CT � 06902
    Class A Common Stock07/09/20253220299460
    Katherine Stueland
    333 Ludlow St, North Tower
    6th Floor
    Stamford � CT � 06902
    Class A Common Stock07/29/20252154226838
    Katherine Stueland
    333 Ludlow St, North Tower
    6th Floor
    Stamford � CT � 06902
    Class A Common Stock09/09/20253657468297
    Katherine Stueland
    333 Ludlow St, North Tower
    6th Floor
    Stamford � CT � 06902
    Class A Common Stock09/16/2025105011275556

    144: Remarks and Signature

    Remarks
    Represents approximately 29,283 shares to be sold on behalf of the Reporting Person, including 1) approximately 2,182 shares to be sold in connection with the anticipated vesting of RSUs on October 29, 2025; 2) approximately 3,686 shares to be sold in connection with the anticipated vesting of RSUs on December 9, 2025; 3) approximately 10,557 shares to be sold in connection with the anticipated vesting of RSUs on December 16, 2025; and 4) 12,858 shares to be sold by the Reporting Person pursuant to the Reporting Person's Rule 10b5-1 trading plan adopted on August 16, 2024. Shares sold in the past 3 months by the Reporting Person include: 1) 16,312 shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs; and 2) 12,877 shares in connection with sales pursuant to the Reporting Person's Rule 10b5-1 trading plan adopted on August 16, 2024.
    Date of Notice
    09/30/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/16/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Katherine Stueland

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $WGS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WGS

    DatePrice TargetRatingAnalyst
    7/9/2025$110.00Overweight
    Piper Sandler
    5/15/2025$88.00Buy
    Guggenheim
    5/9/2025$80.00Hold → Buy
    Jefferies
    8/28/2024$34.00Equal Weight
    Wells Fargo
    7/10/2024$43.00Buy
    Craig Hallum
    6/3/2024$21.00Hold
    Jefferies
    More analyst ratings

    $WGS
    SEC Filings

    View All

    SEC Form 144 filed by GeneDx Holdings Corp.

    144 - GeneDx Holdings Corp. (0001818331) (Subject)

    9/30/25 8:04:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Holdings Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GeneDx Holdings Corp. (0001818331) (Filer)

    9/18/25 8:16:49 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form EFFECT filed by GeneDx Holdings Corp.

    EFFECT - GeneDx Holdings Corp. (0001818331) (Filer)

    9/11/25 12:15:08 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth

    Truveta co‑founder and longtime Microsoft leader joins Executive Leadership Team GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx's next phase of transformation, advancing data and information services across biopharma, health systems, and other partners to accelerate the company's long-term vision of enabling precision medicine. As Chief Business Officer, Gurry will architect and operate GeneDx's strategic business operations and partnership models that open doors and create opportunities t

    9/30/25 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference

    Infinity fuels industry-leading ExomeDx™ and GenomeDx™ testing, delivering the fastest and most accurate rare disease diagnoses Trusted as the #1 ranked genomic testing brand among pediatric and genetic providers GeneDx (NASDAQ: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx's Infinity, the company's proprietary dataset, at the American Academy of Pediatrics (AAP) National Conference & Exhibition taking place this weekend September 26 to 30 in Denver, CO. Infinity is the largest rare disease dataset and is one of the most powerful resources to accelerate diagnosis and fuel drug discovery. It serve

    9/25/25 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Thomas Fuchs, Dr.sc., Chief AI Officer at Eli Lilly and Company, to its board of directors. "With the world's largest rare disease data set, we're only beginning to realize AI's full potential to deliver faster, more precise insights to clinicians and families, accelerating answers for those who need them most," said Katherine Stueland, President and CEO of GeneDx. "Dr. Fuchs' experience scaling AI and machine learning infrastructure and algorithms for practical, high-impact applications in diagnostic medicine is invaluable. We both share the goal of unlocking

    9/18/25 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Fuchs Thomas

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    9/19/25 4:11:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 3 filed by new insider Fuchs Thomas

    3 - GeneDx Holdings Corp. (0001818331) (Issuer)

    9/19/25 4:10:21 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares, increasing direct ownership by 136% to 12,483 units (SEC Form 4)

    4/A - GeneDx Holdings Corp. (0001818331) (Issuer)

    9/18/25 9:50:47 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. bought $3,007,997 worth of shares (50,000 units at $60.16) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/16/25 4:00:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $5,600,994 worth of shares (100,000 units at $56.01) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/12/25 7:46:55 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Casdin Capital, Llc bought $2,757,117 worth of shares (130,000 units at $21.21) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    6/5/24 8:45:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on GeneDx with a new price target

    Piper Sandler initiated coverage of GeneDx with a rating of Overweight and set a new price target of $110.00

    7/9/25 8:30:02 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Guggenheim initiated coverage on GeneDx with a new price target

    Guggenheim initiated coverage of GeneDx with a rating of Buy and set a new price target of $88.00

    5/15/25 8:11:58 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx upgraded by Jefferies with a new price target

    Jefferies upgraded GeneDx from Hold to Buy and set a new price target of $80.00

    5/9/25 8:38:50 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Financials

    Live finance-specific insights

    View All

    GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

    Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue Expanded adjusted gross margin to 71% and generated adjusted net income1 of $15.0 million for the second quarter 2025 Raised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue Announced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability Hosting conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved hea

    7/29/25 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025. Management will host a conference call that day to discuss second quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone

    7/10/25 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

    Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

    4/30/25 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Leadership Updates

    Live Leadership Updates

    View All

    GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth

    Truveta co‑founder and longtime Microsoft leader joins Executive Leadership Team GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx's next phase of transformation, advancing data and information services across biopharma, health systems, and other partners to accelerate the company's long-term vision of enabling precision medicine. As Chief Business Officer, Gurry will architect and operate GeneDx's strategic business operations and partnership models that open doors and create opportunities t

    9/30/25 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Thomas Fuchs, Dr.sc., Chief AI Officer at Eli Lilly and Company, to its board of directors. "With the world's largest rare disease data set, we're only beginning to realize AI's full potential to deliver faster, more precise insights to clinicians and families, accelerating answers for those who need them most," said Katherine Stueland, President and CEO of GeneDx. "Dr. Fuchs' experience scaling AI and machine learning infrastructure and algorithms for practical, high-impact applications in diagnostic medicine is invaluable. We both share the goal of unlocking

    9/18/25 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/19/24 8:00:24 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/8/24 5:23:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology